The importance of identifying affordable and effective ways of preventing cardiovascular diseases (CVDs) as well as reducing their outcomes is fully acknowledged by dieticians. To address the nutrition issues and correct nutrition deficiencies, dieticians explore different approaches. One of the approaches is employing biologically active food supplements (BAFSs) in combination with the main treatment. BAFSs are concentrated sources of various nutrients like minerals, vitamins, fibre, amino acids, essential fatty acids, as well as herbal and plant extracts. The current paper presents the findings of the clinical trial aimed to examine a new BAFS for patients with dyslipidemia and hypertension. Traditional methods of laboratory and clinical trials were used to monitor ailments and complaints and to assess physical health. The ingredients for the new BAFS include (mg per 1 capsule): L-carnitine – 22.5; polyprenols – 5; lycopene – 0.625; tocopherol acetate – 3.75; coenzyme Q10 – 3.75. The patients who received the new BAFS demonstrated improved memory, reduced headaches, fatigue, and dizziness. There were significant changes in the indicators for the health-related quality of life (physical activity, sleep, emotional state, social functioning). The Giessen Subjective Complaints List, which is a scientifically sound assessment of subjective health complaints, was applied to document exhaustion, gastrointestinal, musculoskeletal and cardiovascular complaints. Positive changes in blood pressure levels and lipid profiles were recorded. The findings of the trial revealed reduced cholesterol and triglycerides, improved overall health and well-being in patients prescribed the new BAFS along with the main treatment.